Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Njinsky Ambispective Cellular Product Safety and Outcomes Registry

A legfontosabb adatok

Ki végzi
Njinsky Medical Centre
Hol
Pakisztán1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
1200 fő, tervezett
Kezdés
2026. dec. 1.
Várható befejezés
2032. dec. 30.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A vizsgált kezelések
  • Umbilical Cord Mesenchymal Stem Cells
  • Stromal Vascular fraction
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 8 feltétel megnézéseKevesebb

Ki vehet részt

  • The clinical record documents a diagnosis in at least one registry cohort: retinitis pigmentosa, autism spectrum disorder, a female fertility condition, or azoospermia
  • The participant received at least one routine-care administration of cultured umbilical cord mesenchymal stromal cells, autologous uncultured stromal vascular fraction, or both at Njinsky Medical Centre during the registry period
  • Retrospective records are included only when use of the data is covered by consent or other authorization approved by the Institutional Review Board
  • Prospective participants agree to registry inclusion under the approved consent process
  • For minors, guardian permission and age-appropriate assent are obtained as required by the approved process

Ki nem vehet részt

  • No qualifying diagnosis is documented
  • No eligible routine-care administration can be verified
  • There is no valid consent or other Institutional Review Board-approved basis to use the participant's data

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both as part of routine care at Njinsky Medical Centre. The registry includes separate cohorts for retinitis pigmentosa, autism spectrum disorder, female infertility conditions, and azoospermia. The retrospective component will use eligible routine-care records from 1 January 2020 through 30 November 2026. Prospective enrollment is planned from 1 December 2026 through 31 December 2030, with follow-up at 1, 3, 6, 12 and 24 months after the last treatment session. Patients may be followed by phone or in person. The study will not assign treatment or require additional tests; it will record measures obtained in routine care and information reported or documented at follow-up. Results will be described separately by condition and actual product exposure. The registry is not designed by itself to establish that a product caused a clinical outcome.

A vizsgálat 4 csoportja

  • Retinitis Pigmentosa

    Patients diagnosed with retinitis pigmentosa in routine care who receive an eligible UCMSC and/or SVF administration at Njinsky Medical Centre.

    Kezelés: Umbilical Cord Mesenchymal Stem Cells és Stromal Vascular fraction

  • Autism Spectrum Disorder

    Patients diagnosed with autism spectrum disorder in routine care who receive an eligible administration. Children may be included; use guardian permission and age-appropriate assent as required by the IRB-approved process.

    Kezelés: Umbilical Cord Mesenchymal Stem Cells

  • Female infertility conditions

    Patients receiving routine care for female fertility conditions, primarily diminished/low ovarian reserve, secondary infertility and amenorrhea, who receive an eligible administration. Record the specific diagnosis per patient.

    Kezelés: Umbilical Cord Mesenchymal Stem Cells és Stromal Vascular fraction

  • Azoospermia

    Patients diagnosed with azoospermia in routine care who receive an eligible administration. Record obstructive/non-obstructive classification when available.

    Kezelés: Umbilical Cord Mesenchymal Stem Cells és Stromal Vascular fraction

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Disease-Specific Outcomes Following Routine-Care Use of Cultured UCMSCs and/or Autologous Uncultured SVF Across Multiple Indications: An Ambispective Observational Registry
A regiszteradat frissítve
2026. november 17.